AMDL strengthens IVD focus with Dx subsidiary
This article was originally published in Clinica
Executive Summary
Pharmaceutical company AMDL has created a new subsidiary, AMDL Diagnostics (ADI), which will focus exclusively on the development and commercialisation of its cancer test Onko-Sure.